Literature DB >> 22274810

Nine years of experience with the sentinel lymph node biopsy in a single Italian center: a retrospective analysis of 1,050 cases.

Sergio Bernardi1, Serena Bertozzi, Ambrogio P Londero, Francesco Giacomuzzi, Vito Angione, Cinzia Dri, Arnalda Carbone, Roberto Petri.   

Abstract

BACKGROUND: This study aims to determine the prevalence and predictive factors for recurrence after sentinel lymph node biopsy (SLNB) and for sentinel lymph node positivity by SLNB in our population.
METHODS: We followed up all SLNBs performed between 2002 and 2010 and analyzed data by R (version2.10.1), considering p < 0.05 significant.
RESULTS: Among 1,050 patients with SLNB, 23% (245/1050) underwent secondary axillary dissection (CALND). Axillary recurrence prevalence among patients with negative SLNB was 1% (6/805) at a mean follow-up of 54 months (±14), and 1.7% (95% CI 0.2-3.1%) after 6 years of follow-up, as all recurrences developed between the 3rd and the 6th years of follow-up. By multivariate analysis, axillary recurrence results correlated with large tumor size, high number of excised nodes, lymphovascular invasion, high grading, multifocality, Her-2 positivity, intraductal histology, and comedo-like necrosis. Moreover, SLNB positivity results correlated with young age, large tumor size, high number of excised nodes, negative history for second primary malignancies, lymphovascular invasion, and high grading.
CONCLUSIONS: Cancer characteristics represent important predictive factors for SLNB positivity, as well as for axillary recurrence in patients with negative SLNB, independently, by surgical and nonsurgical treatment. Therefore, cancer biological behavior and the patient's hormonal profile should be evaluated with care to better tailor the follow-up of women with breast cancer.

Entities:  

Mesh:

Year:  2012        PMID: 22274810     DOI: 10.1007/s00268-011-1420-0

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  45 in total

1.  The evolution of surgery for breast cancer.

Authors:  David P Winchester; Lucrecia Trabanino; Marvin J Lopez
Journal:  Surg Oncol Clin N Am       Date:  2005-07       Impact factor: 3.495

2.  Survival after bilateral breast cancer: results from a population-based study.

Authors:  Helena M Verkooijen; Vanessa Chatelain; Gérald Fioretta; Georges Vlastos; Elisabetta Rapiti; André-Pascal Sappino; Christine Bouchardy; Pierre O Chappuis
Journal:  Breast Cancer Res Treat       Date:  2006-12-21       Impact factor: 4.872

3.  Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden.

Authors:  Amy Cyr; William E Gillanders; Rebecca L Aft; Timothy J Eberlein; Feng Gao; Julie A Margenthaler
Journal:  Ann Surg Oncol       Date:  2010-09-19       Impact factor: 5.344

4.  Effect of occult metastases on survival in node-negative breast cancer.

Authors:  Donald L Weaver; Takamaru Ashikaga; David N Krag; Joan M Skelly; Stewart J Anderson; Seth P Harlow; Thomas B Julian; Eleftherios P Mamounas; Norman Wolmark
Journal:  N Engl J Med       Date:  2011-01-19       Impact factor: 91.245

5.  Sentinel node biopsy and quality of life measures in a Chinese population.

Authors:  J-J Chen; X-Y Huang; Z-B Liu; T-W Chen; J-Y Cheng; W-T Yang; W-P Xu; Z-M Shao; Z-Z Shen; J Wu
Journal:  Eur J Surg Oncol       Date:  2009-02-23       Impact factor: 4.424

6.  Omitting axillary lymph node dissection in sentinel node negative breast cancer patients is safe: a long term follow-up analysis.

Authors:  Hans Torrenga; Hans Fabry; Joost R M van der Sijp; Paul J van Diest; Rik Pijpers; Sybren Meijer
Journal:  J Surg Oncol       Date:  2004-10-01       Impact factor: 3.454

7.  Axillary recurrence after negative sentinel lymph node biopsy.

Authors:  Hee Jeong Kim; Byung Ho Son; Eun Wha Park; Woo Sung Lim; Jin Young Seo; Mi Ae Jang; Bo Kyong Ku; Sei Hyun Ahn
Journal:  Breast Cancer Res Treat       Date:  2008-04-04       Impact factor: 4.872

8.  Gamma probe-guided sentinel node biopsy--optimal timing for injection.

Authors:  S Schneebaum; J Stadler; M Cohen; D Yaniv; J Baron; Y Skornick
Journal:  Eur J Surg Oncol       Date:  1998-12       Impact factor: 4.424

9.  Axillary metastases in breast cancer patients with negative sentinel nodes: a follow-up of 3548 cases.

Authors:  Umberto Veronesi; Viviana Galimberti; Giovanni Paganelli; Patrick Maisonneuve; Giuseppe Viale; Roberto Orecchia; Alberto Luini; Mattia Intra; Paolo Veronesi; Pietro Caldarella; Giuseppe Renne; Nicole Rotmensz; Claudia Sangalli; Luciana De Brito Lima; Marco Tullii; Stefano Zurrida
Journal:  Eur J Cancer       Date:  2009-01-06       Impact factor: 9.162

10.  Sentinel node biopsy in breast cancer patients with large or multifocal tumors.

Authors:  Tuomo J Meretoja; Marjut H Leidenius; Päivi S Heikkilä; Heikki Joensuu
Journal:  Ann Surg Oncol       Date:  2009-02-26       Impact factor: 5.344

View more
  7 in total

1.  Impact of the presence and quantity of ductal carcinoma in situ component on the outcome of invasive breast cancer.

Authors:  Carla Cedolini; Serena Bertozzi; Ambrogio P Londero; Luca Seriau; Michela Andretta; Diane Agakiza; Sandro Fongione; Alessandro Uzzau; Andrea Risaliti
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

2.  One-Step Nucleic Acid Amplification System in Comparison to the Intraoperative Frozen Section and Definitive Histological Examination Among Breast Cancer Patients: A Retrospective Survival Study.

Authors:  Serena Bertozzi; Ambrogio P Londero; Michela Bulfoni; Luca Seriau; Diane Agakiza; Alberto Pasqualucci; Michela Andretta; Maria Orsaria; Laura Mariuzzi; Carla Cedolini
Journal:  Front Oncol       Date:  2022-05-18       Impact factor: 5.738

3.  Influence of surgical margins on the outcome of breast cancer patients: a retrospective analysis.

Authors:  Sergio Bernardi; Serena Bertozzi; Ambrogio P Londero; Giuliana Gentile; Vito Angione; Roberto Petri
Journal:  World J Surg       Date:  2014-09       Impact factor: 3.352

4.  Eight-year experience with the intraoperative frozen section examination of sentinel lymph node biopsy for breast cancer in a North-Italian university center.

Authors:  Carla Cedolini; Serena Bertozzi; Luca Seriau; Ambrogio P Londero; Serena Concina; Federico Cattin; Onelio Geatti; Carla Di Loreto; Andrea Risaliti
Journal:  Int J Clin Exp Pathol       Date:  2013-12-15

5.  Sentinel Lymph Node Biopsy in T3 and T4b Breast Cancer Patients: Analysis in a Tertiary Cancer Hospital and Systematic Literature Review.

Authors:  Idam de Oliveira-Junior; Eliana Aguiar Petri Nahas; Ana Cristina Cherem; Jorge Nahas-Neto; René Aloisio da Costa Vieira
Journal:  Breast Care (Basel)       Date:  2020-03-27       Impact factor: 2.860

6.  TFEB, SIRT1, CARM1, Beclin-1 expression and PITX2 methylation in breast cancer chemoresistance: a retrospective study.

Authors:  Serena Bertozzi; Ambrogio P Londero; Luigi Viola; Maria Orsaria; Michela Bulfoni; Stefania Marzinotto; Bruna Corradetti; Umberto Baccarani; Daniela Cesselli; Carla Cedolini; Laura Mariuzzi
Journal:  BMC Cancer       Date:  2021-10-18       Impact factor: 4.430

7.  Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer.

Authors:  Serena Bertozzi; Ambrogio P Londero; Carla Cedolini; Alessandro Uzzau; Luca Seriau; Sergio Bernardi; Stefano Bacchetti; Enrico Maria Pasqual; Andrea Risaliti
Journal:  Springerplus       Date:  2015-11-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.